CN1717245A - Medicinal composition - Google Patents
Medicinal composition Download PDFInfo
- Publication number
- CN1717245A CN1717245A CNA2003801043061A CN200380104306A CN1717245A CN 1717245 A CN1717245 A CN 1717245A CN A2003801043061 A CNA2003801043061 A CN A2003801043061A CN 200380104306 A CN200380104306 A CN 200380104306A CN 1717245 A CN1717245 A CN 1717245A
- Authority
- CN
- China
- Prior art keywords
- weight portions
- medicine
- application
- medical composition
- bulbus allii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A medicinal composition containing an antipyretic, analgesic and antiinflammatory agent and a processed garlic product. This medicinal composition exerts excellent antipyretic, analgesic and antiinflammatory effects even in a small dose with relieved side effects of, for example, injuring the gastric mucosa.
Description
Technical field
The present invention relates to the medical composition of the good and few side effects of anti inflammation and heat resolution analgesic effect.
Background technology
In order to have a headache, toothache, menstrual pain, arthralgia, myalgia, the analgesia of pharyngalgia etc., the swollen alleviation that waits inflammatory symptom of larynx, or suppress the heating of disease initiations such as flu, headache, various inflammation etc., can use and be combined with the propanoic acid class medicine of ibuprofen as representative, piroxicam is former times health (oxicam) the class medicine of representative, aspirin is the salicylic acid medicine of representative, acetaminophen is the phenyl amines medicine of representative, disalicylic acid is the pyrazoline ketone medicine of representative, indomethacin is the preparation of the anti inflammation and heat resolution analgesic such as heteroauxing class medicine of representative, as the anti inflammation and heat resolution analgesic.Yet the majority of these anti inflammation and heat resolution analgesic has the side effect of gastric mucosa injury etc., and existence can not increase dosage to obtain the problem of enough anti inflammation and heat resolution analgesic effect.Therefore wish to have the curative that does not increase dosage and obtain high anti inflammation and heat resolution analgesic effect.
Summary of the invention
Therefore, the purpose of this invention is to provide low dosage and also have good anti inflammation and heat resolution analgesic activity, alleviate the medical composition of the side effect of gastric mucosa injury etc. simultaneously.
Consider this present situation, the result that the present inventor furthers investigate, be surprised to find that anti inflammation and heat resolution analgesic and Bulbus Allii elaboration products share, can strengthen significantly that the anti inflammation and heat resolution analgesic is analgesic, analgesia, antiinflammation, when low dosage, show good anti inflammation and heat resolution analgesic activity, alleviate side effect such as gastric mucosa injury, finished the present invention.
Promptly the invention provides and contain anti inflammation and heat resolution analgesic and Bulbus Allii elaboration products medical composition.
The Bulbus Allii elaboration products; people known except that set up and the strengthening by means of tonics effect; also have stomach contractility potentiation, new battle array metabolism facilitation, blood flow facilitation, liver protection etc., but do not know that fully the effect of antiinflammatory antipyretic analgesic is had enhanced effect.
Medical composition of the present invention can alleviate side effect such as gastric mucosa injury, and low dosage also has good anti inflammation and heat resolution analgesic activity.
Description of drawings
Fig. 1 shows to throw to the time dependent figure of edema volume behind the carrageenin.Throw in carrageenin each medicine of orally give before preceding 0.5 hour.
Fig. 2 shows orally give matched group, acetaminophen list medicine or share acetaminophen and the figure of the edema index (edema index) during ォ キ ソ ア ミ ヂ Application (Oxo-amidin) smalls.
Fig. 3 shows orally give matched group, ethenzamide list medicine or share ethenzamide and the figure of the edema index (edema index) during ォ キ ソ ア ミ ヂ Application smalls.
Fig. 4 shows orally give matched group, ibuprofen list medicine or share ibuprofen and the figure of the edema index (edema index) during ォ キ ソ ア ミ ヂ Application smalls.
The specific embodiment
The anti inflammation and heat resolution analgesic that uses for the present invention is not particularly limited, and can exemplify propanoic acid class medicines such as ibuprofen, loxoprofen sodium, ketoprofen; Former times health class medicine such as piroxicam; Salicylic acid medicines such as aspirin, aluminium aspirin, ethenzamide, salicylamide, sodium salicylate; Phenyl amines medicines such as acetaminophen, phenacetin, lacto ethyl phenyl ether; Pyrazoline ketone medicines such as disalicylic acid, isopropylantipyrine, phenazone, dipyrone; And heteroauxing class medicine such as acemetacin, indomethacin etc.
As the anti inflammation and heat resolution analgesic, better be propanoic acid class medicine, salicylic acid medicine, phenyl amines medicine, pyrazoline ketone medicine and indoles medicine.Propanoic acid class medicine better is ibuprofen, loxoprofen sodium; The salicylic acid medicine better is aspirin, ethenzamide; The phenyl amines medicine better is an acetaminophen; Pyrazoline ketone medicine better is an isopropylantipyrine; The indoles medicine better is an indomethacin.
The Bulbus Allii elaboration products that the present invention uses are that the bulb of Liliaceae Allium Bulbus Allii (Allium sativum L.) gets through processed.Processed is for example with powdered after the living Bulbus Allii drying, or living Bulbus Allii extracts through vapor distillation, with oil, water, hot water or water-miscible organic solvent etc. and handle, or living Bulbus Allii is through processing such as heating.The oil that is used to extract can exemplify vegetable oil, olive oil, Semen sojae atricolor wet goods edible vegetable oil; Water-miscible organic solvent can exemplify glycol such as lower alcohols such as ethanol, isopropyl alcohol, propylene glycol, diethylene glycol etc.
As the Bulbus Allii elaboration products, so long as above-mentioned elaboration products are not particularly limited.For example, better be processing Bulbus Allii, garlic extract, Bulbus Allii extractum, dry Bulbus Allii etc., good especially is the processing Bulbus Allii.But, the processing Bulbus Allii is with the garlic extract of heat treated garlic or the extractum through the preparation of operations such as lower alcohol extraction, the ォ キ ソ ア ミ ヂ Application of selling as the market (registered trade mark) (reason is ground chemical industry Co., Ltd. system), ォ キ ソ ア ミ ヂ Application (registered trade mark) smalls (reason is ground chemical industry Co., Ltd. system), ォ キ ソ レ ヂ Application (Oxo-Reduin) (registered trade mark) (reason is ground chemical industry Co., Ltd. system), ォ キ ソ レ ヂ Application (registered trade mark) smalls (reason is ground chemical industry Co., Ltd. system) etc.Bulbus Allii extractum, the Bulbus Allii extractum of selling as the market (ア Le プ ス pharmaceutical industries Co., Ltd. system), Bulbus Allii fluid extract (Japanese powder pharmaceutical Co., Ltd. system) etc.Dry Bulbus Allii is as Bulbus Allii powder, dry Bulbus Allii powder EX (reason is ground chemical industry Co., Ltd. system) etc.In these Bulbus Allii elaboration products that sell the market, better be ォ キ ソ ア ミ ヂ Application (registered trade mark) (reason is ground chemical industry Co., Ltd. system), ォ キ ソ ア ミ ヂ Application (registered trade mark) smalls (reason is ground chemical industry Co., Ltd. system), ォ キ ソ レ ヂ Application (registered trade mark) (reason is ground chemical industry Co., Ltd. system), ォ キ ソ レ ヂ Application (registered trade mark) smalls (reason is ground chemical industry Co., Ltd. system) etc.
The content weight ratio of anti inflammation and heat resolution analgesic and Bulbus Allii elaboration products in the medical composition of the present invention, the anti inflammation and heat resolution analgesic: the Bulbus Allii elaboration products be 20000: 1～1: 600 better, 1500: 1～1: 300 better, and 150: 1～1: 150 good especially, and 100: 1～1: 50 best.Calculate this content than the time, the weight of Bulbus Allii elaboration products is used to deduct the weight of extracting solvent when solvent extractable matter, uses the dry weight that deducts moisture in other occasions.
Medical composition of the present invention is used to have a headache, the analgesia of toothache, menstrual pain, arthralgia, myalgia, pharyngalgia etc.The swollen alleviation that waits inflammatory symptom of larynx, and flu is effective for the remission of the flu disease of representative etc.
Medical composition of the present invention, can suitably cooperate the anti inflammation and heat resolution analgesic of requirement and the effective ingredient beyond the Bulbus Allii elaboration products as required, as antihistaminic, cough medicine, expectorant, anticholinergic agent, sympathetic activation agent, central stimulant, hypnotic and sedative, antifibrinolysin medicine, anti-inflammatory agent, antiinflammatory enzyme, vitamin drug, antacid, crude drug etc.
As antihistaminic, can exemplify antol (Sumitomo) preferably, diphenylpyraline hydrochloride, diphhydramine hydrochloride, the hydrochloric acid difeterol, triprolidine hydrochloride, tripelennamine hydrochloride, hydrochloric acid ト Application ジ Le ア ミ Application (thonzylamine hydrochloride), the hydrochloric acid fenethazine, hydrochloric acid メ ト ジ ラ ジ Application (methdilazinehydrochloride), promethazine hydrochloride, diphenhydramine salicylate, biphenyl disulfonic acid carbinoxamine, alimemazine tartrate, diphenhydramine tannate, tea chloric acid (theoclicacid) diphenylpyraline, the naphthalenedisulfonic acid mebhydrolin, promethazine methylene two Salicylates, carbinoxamine maleate, the dl-chlorphenamine maleate, the d-chlorphenamine maleate, the phosphoric acid difeterol, clemastine fumarate etc.; Can exemplify Hexacol, hydrochloric acid cloperastine, citric acid pentoxifylline, citric acid tipepidine, sodium dibunate, dextromethorphan hydrobromide, dextromethorphan, phenolphthalein salt, ヒ ベ Application ズ acid tipepidine (tipepidine hibenzoate), Off エ Application ジ ゾ acid cloperastine (cloperastine fendizoate), codeine phosphate, dihydrocodeine phosphate, Gnoscopine hydrochloride., narcotine etc. as anti-tussive agents; Can exemplify sulfogaiacol, guaifenesin, Bisolvon etc. as expectorant; As anticholinergic agent, available isopropamide iodide, dicyclomine hydrochloride, scopolamine butylbromide, Semen daturae total alkaloids etc.; As the sympathetic activation agent, can exemplify dl-hydrochloric acid methylephedrine, dl-methylephedrine saccharin salt, phenylpropanolamine HC1, pseudoephedrine hydrochloride etc.; Can exemplify Caffeine Anhydrous, caffeine, caffeine sodium benzoate etc. as central stimulant; As hypnotic and sedative, can enumerate Bromovalerylurea, allyl isopropylacetyl urea etc.; As the antifibrinolysin medicine, can enumerate tranexamic acid etc.; As anti-inflammatory agent, can enumerate enoxolone and analog thereof etc.; Can exemplify lysozyme chloride, bromelain, Serrapeptase etc. as the antiinflammatory enzyme; As vitamin drug, can enumerate vitamin B
1And derivant and their salt, vitamin B
2And derivant and their salt, vitamin C and derivant thereof and their salt, Hesperidin and derivant thereof and their salt etc.; As antacid, can enumerate glycine, magnesium silicate, synthetic aluminium silicate, synthetic hydrotalcite, magnesium oxide, dihydroxyaluminum aminoacetate (aluminum glycinate), gel aluminum hydroxide, dried aluminum hydroxide gel, the aluminium hydroxide magnesium carbonate is mixed in gel, aluminium hydroxide sodium bicarbonate coprecipitate, aluminium hydroxide calcium carbonate magnesium carbonate coprecipitate, magnesium hydroxide aluminium potassium sulfate coprecipitate, magnesium carbonate, aluminosilicate magnesium gel etc.; As crude drug dragon, Radix Glycyrrhizae, siliceous skin, Pericarpium Zanthoxyli, Valeriana officinalis var. latifolia, Radix Ginseng etc. enumerably.
In addition, but appropriate combination is used the pharmaceutically carrier of permission in the medical composition of the present invention, as excipient such as lactose, starch based, crystalline cellulose, sucrose, mannitol, light silicon dioxide, calcium hydrogen phosphate, sodium chloride, glucose, calcium carbonate, Kaolin, silicic acid; Binding agents such as water, ethanol, propanol, simple syrup, glucose solution, starch fluid, gelatin solution, carmellose, hyprolose, hydroxypropyl starch, methylcellulose, ethyl cellulose, Lac, calcium phosphate, polyvinylpyrrolidone, alphalysed starch, amylopectin; Disintegrating agents such as low degree of substitution hyprolose, dry starch, sodium alginate, agar end, sodium bicarbonate, calcium carbonate, sodium lauryl sulphate, sweet monostearate, lactose, carboxymethylcellulose calcium, corn starch; Lubricants such as Talc, magnesium stearate, Borax, Polyethylene Glycol; Coloring agent such as chocolate pigment, iron sesquioxide; Correctivess such as sucrose, Pericarpium Citri junoris, citric acid, tartaric acid, steviosin, aspartame; Buffer agents such as sodium citrate; Stabilizing agents such as tragacanth, arabic gum, gelatin, use flavoring agent also capable of being combined as required, extender, surfactant, dispersant, antiseptic, spice etc.
The form of medication of medical composition of the present invention, can exemplify with tablet, capsule, granule, powder, liquor, syrup etc. oral, or with non-oral agents such as smearss such as gel, ointment, suppository, patches.
Medical composition of the present invention above-mentioned raw materials manufacturing when being made into preparation, can be used common formulation method.
The dosage of medical composition of the present invention can be according to kind, its combination and variation of anti inflammation and heat resolution analgesic and Bulbus Allii elaboration products, and in addition, also body weight, age, sex, symptom, form of medication and the administration number of times etc. according to the patient change.Usually, generally when becoming human oral, the total amount of anti inflammation and heat resolution analgesic and Bulbus Allii elaboration products better is 6～10500mg/ day.The each dosage of anti inflammation and heat resolution analgesic better is that 5～2000mg, Bulbus Allii elaboration products are 0.1～1500mg.
When oral, can take 1～several times every day.
Embodiment
Below, enumerate embodiment and describe the present invention in detail, but the invention is not restricted to these embodiment.
The Wistar that gives one night of fasting be the male rat oral suspension in 0.5 weight % methocel solution for reagent, the administration volume is 2mL/kg.In the subcutaneous carrageenin 0.1mL that gives 1 weight % of the right side foot sole of the foot, give carrageenin certainly and begin after 1 hour after 30 minutes,, per hour measure sufficient volume up to 6 hours.Edema suppresses the mensuration of effect, divide matched group (giving 0.5 weight % methocel solution), ibuprofen administration group (5mg/kg), (reason is ground chemical industry Co., Ltd. system to ォ キ ソ ア ミ ヂ Application administration group, 100mg/kg) and ibuprofen (5mg/kg) add 4 groups of ォ キ ソ ア ミ ヂ Application (100mg/kg) combination group, measure 4～6 examples for every group.The gained data are carried out statistical analysis by the Tukey multiple comparisons.The result represents with Fig. 1.
Give 1 weight % carrageenin, the edema volume rose with the elapsed time, its maximum, each administration group is all observed after 6 hours giving carrageenin, matched group is 1.27mL, and ibuprofen administration group and ォ キ ソ ア ミ ヂ Application administration group are respectively 0.95mL, 1.18mL, the edema inhibitory action occurs.On the other hand, two medicine combination group are 0.55mL, show than ibuprofen administration group significant inhibitory effect.
Combination group is organized with ibuprofen and is compared, and all shows significant edema inhibitory action at arbitrary minute.
Similarly to Example 1, set the administration group of condition 1～3 shown below, inquire into various anti inflammation and heat resolution analgesic and Bulbus Allii elaboration products and share the effect that edema is suppressed.
Matched group (giving 0.5 weight % methocel solution), acetaminophen administration group (200mg/kg) and to alcohol amido phenol (200mg/kg) and ォ キ ソ ア ミ ヂ Application smalls (4mg/kg) combination group, totally 3 groups, every group 3 example.
Matched group (giving 0.5 weight % methocel solution), salicylamine administration group (50mg/kg) and ethenzamide (50mg/kg) and ォ キ ソ ア ミ ヂ Application smalls (1mg/kg) combination group, totally 3 groups, every group 3 example.
Matched group (giving 0.5 weight % methocel solution), ibuprofen administration group (10mg/kg) and ibuprofen (10mg/kg) and ォ キ ソ ア ミ ヂ Application smalls (0.2mg/kg) combination group, totally 3 groups, every group 3 example.
The degree of every group of edema under each condition is with edema index (edema index) expression.Here the edema index is the area under curve (summation of each minute edema volume addition) from calculating with the same elapsed time one edema volume curve of making of Fig. 1.And the gained data are carried out statistical analysis with the Tukey multiple comparisons.
The result of condition 1 (acetaminophen and ォ キ ソ ア ミ ヂ Application smalls) represents in Fig. 2.The edema index of matched group is 7.00, acetaminophen (200mg/kg) administration group is 4.71, show that edema suppresses tendency, and acetaminophen (200mg/kg) and ォ キ ソ ア ミ ヂ Application smalls (4mg/kg) and group are 3.43, can see significant edema inhibitory action.The method of this external Burgi has been discussed the effect of share of medicine.The edema index of matched group was converted into 1 o'clock, and acetaminophen (200mg/kg) administration group is 0.673, and ォ キ ソ ア ミ ヂ Application smalls (4mg/kg) administration group (not shown) is 0.981, and its long-pending (0.660) is 0.490 bigger than combination group.Therefore, promptly use the method for Burgi, confirm that also two medicines have share positive effect.
The result of condition 2 (ethenzamide and ォ キ ソ ア ミ ヂ Application smalls) represents with Fig. 3.The edema index 7.80 of matched group, ethenzamide (50mg/kg) administration group is 6.21, and visible edema suppresses tendency, and ethenzamide (50mg/kg) is 5.09 with ォ キ ソ ア ミ ヂ Application smalls (1mg/kg) combination group, finds significant edema inhibitory action.In addition, with the same method of condition 1 with Burgi, the edema index of matched group was converted into 1 o'clock, ethenzamide (50mg/kg) group is 0.796, as quote the value (0.981) of ォ キ ソ ア ミ ヂ Application smalls (4mg/kg) administration group in the condition 1, its long-pending (0.781) is 0.653 bigger than combination group.Therefore, promptly use the method for Burgi to confirm that also two medicines have share positive effect.
The result of condition 3 (ibuprofen and ォ キ ソ ア ミ ヂ Application smalls) represents with Fig. 4.Edema index with respect to matched group is 6.24, and ibuprofen (10mg/kg) administration group is 4.35, the swollen tendency that suppresses of water breakthrough, and ibuprofen (10mg/kg) and ォ キ ソ ア ミ ヂ Application smalls (0.2mg/kg) combination group are 3.53, show that significant edema suppresses effect.In addition, be converted into 1 o'clock with the method for Burgi edema index equally with condition 1 matched group, ibuprofen (10mg/kg) administration group is 0.697, as quotes the value (0.981) of condition 1 ォ キ ソ ア ミ ヂ Application smalls (4mg/kg) administration group, and its long-pending (0.684) is 0.566 bigger than combination group.Therefore, with the method for Burgi, confirm that also two medicines have share remarkable result.
Make the medical composition of Production Example 1～10 shown below.
Production Example 1
Ibuprofen 450 weight portions, Bromovalerylurea 600 weight portions, Caffeine Anhydrous 75 weight portions, ォ キ ソ ア ミ ヂ Application smalls (reason is ground chemical industry Co., Ltd. system) 90 weight portions, vitamin C 300 weight portions, hyprolose 81 weight portions, low degree of substitution hyprolose 405 weight portions, crystalline cellulose 672 weight portions are mixed, add water 250 weight portions again, wet granulation.After the drying, add magnesium stearate 27 weight portions, use tablet machine (chrysanthemum water is made the コ レ of institute Network ト 19TU), the tablet of press forming 300mg/ sheet.
Production Example 2
Aspirin 1500 weight portions, allyl isopropylacetyl urea 180 weight portions, Caffeine Anhydrous 75 weight portions, ォ キ ソ ア ミ ヂ Application smalls (reason is ground chemical industry Co., Ltd. system) 50 weight portions, hyprolose 104.5 weight portions, low degree of substitution hyprolose 472.5 weight portions, crystalline cellulose 736.5 weight portions are mixed, add ethanol 300 weight portions again, wet granulation.After the drying, add magnesium stearate 31.5 weight portions, with the Production Example 1 same tablet of making the 350mg/ sheet.
Production Example 3
With acetaminophen 900 weight portions, d-chlorphenamine maleate (chlorphenamine) 3.5 weight portions, ヒ ベ Application ズ acid tipepidine, dl-hydrochloric acid methylephedrine 60 weight portions, sulfogaiacol 250 weight portions, tranexamic acid 420 weight portions, Caffeine Anhydrous 75 weight portions, Semen daturae total alkaloids 0.3 weight portion, ォ キ ソ ア ミ ヂ Application smalls (reason is ground chemical industry Co., Ltd. system) 60 weight portions, hyprolose 94.5 weight portions, low degree of substitution hyprolose 472.5 weight portions, crystalline cellulose 707.7 weight portions mix, add ethanol 300 weight portions again, wet granulation.After the drying, add magnesium stearate 31.5 weight portions, with the Production Example 1 same tablet of making the 350mg/ sheet.
Production Example 4
Ibuprofen 450 weight portions, clemastine fumarate 1.34 weight portions, dihydrocodeine phosphate 24 weight portions, Gnoscopine hydrochloride. 48 weight portions, guaifenesin 250 weight portions, Caffeine Anhydrous 75 weight portions, ォ キ ソ ア ミ ヂ Application smalls (reason is ground chemical industry Co., Ltd. system) 100 weight portions, hyprolose 54 weight portions, low degree of substitution hyprolose 270 weight portions, crystalline cellulose 509.66 weight portions are mixed, add water 450 weight portions again, wet granulation.Add magnesium stearate 18 weight portions after the drying, same with Production Example 1, the tablet of manufacturing 350mg/ sheet.
Production Example 5
Acetaminophen 390 weight portions, ethenzamide 850 weight portions, d-chlorphenamine maleate 3.5 weight portions, ヒ ベ Application ズ acid tipepidine 75 weight portions, dl-hydrochloric acid methylephedrine 60 weight portions, tranexamic acid 420 weight portions, Caffeine Anhydrous 75 weight portions, Semen daturae total alkaloids 0.3 weight portion, ォ キ ソ ア ミ ヂ Application smalls 50 weight portions, hyprolose 94.5 weight portions, low degree of substitution hyprolose 472.5 weight portions, crystalline cellulose 627.7 weight portions are mixed, with ethanol 300 weight portion wet granulations.After the drying, add magnesium stearate 31.5 weight portions, with the Production Example 1 same tablet of making the 350mg/ sheet.
Production Example 6
With ethenzamide 850 weight portions, d-chlorphenamine maleate 3.5 weight portions, ヒ ベ Application ズ acid tipepidine 75 weight portions, dl-hydrochloric acid methylephedrine 60 weight portions, sulfogaiacol 250 weight portions, tranexamic acid 420 Caffeine Anhydrous 75 weight portions, Semen daturae total alkaloids 0.3 weight portion, ォ キ ソ ア ミ ヂ Application smalls 60 weight portions, hyprolose 94.5 weight portions, low degree of substitution hyprolose 472.5 weight portions, crystalline cellulose 757.7 weight portions mix, with ethanol 300 weight portion wet granulations.After the drying, add magnesium stearate 31.5 weight portions, with the Production Example 1 same tablet of making the 350mg/ sheet.
Production Example 7
ォ キ ソ ア ミ ヂ Application smalls (reason is ground chemical industry Co., Ltd. system) 90g, d-chlorphenamine maleate 3.5g, dihydrocodeine phosphate 24g, dl-hydrochloric acid methylephedrine 60g, guaifenesin 250g, Caffeine Anhydrous 75g, citric acid 60g, para hydroxybenzene ethyl ester 1.8g, para hydroxybenzene propyl ester 0.9g, para hydroxybenzene butyl ester 0.9g, sodium benzoate 54g, refined sucrose 22500g, 30 POVIDONE K 30 BP/USP 90 540g are mixed, add Purified Water 60L, humidification stirs, dissolving.To wherein adding suitable sodium citrate, regulating pH is 3.5.Add crystalline cellulose carmethose 540g to it, acetaminophen 900g makes uniform suspension with homogenizer.After the cooling, perfuming 90g and an amount of Purified Water, making total amount is 90L.
With its filled drink bottle, every bottle of 30mL behind the close plug, in 75 ℃ of heating 30 minutes, carries out sterilization treatment.
Production Example 8
Loxoprofen sodium 180 weight portions, Bromovalerylurea 600 weight portions, Caffeine Anhydrous 75 weight portions, ォ キ ソ ア ミ ヂ Application smalls (reason is ground chemical industry Co., Ltd. system) 90 weight portions, vitamin C 500 weight portions, hyprolose 81 weight portions, low degree of substitution hyprolose 475 weight portions, crystalline cellulose 672 weight portions are mixed, add water 250 weight portions again, wet granulation.After the drying, add magnesium stearate 27 weight portions, same with Production Example 1, the tablet of press forming 300mg/ sheet.
Production Example 9
Isopropylantipyrine 450 weight portions, ethenzamide 750 weight portions, Caffeine Anhydrous 75 weight portions, ォ キ ソ ア ミ ヂ Application smalls (reason is ground chemical industry Co., Ltd. system) 90 weight portions, vitamin C 150 weight portions, hyprolose 81 weight portions, low degree of substitution hyprolose 405 weight portions, crystalline cellulose 672 weight portions are mixed, add water 250 weight portions again, wet granulation.Add magnesium stearate 27 weight portions after the drying, same with Production Example 1, press forming gets the tablet of 300mg/ sheet.
Production Example 10
Indomethacin 1g and ォ キ ソ ア ミ ヂ Application 0.01g are dissolved in propylene glycol 20g and ethanol 30g, the material that the hydroxyl ethene polymers of interpolation water 20g swelling 1g forms, and stir.Add diisopropanolamine (DIPA) 1.1g again and be dissolved in the solution that water 10g forms, add the water of surplus then,, be stirred to fully evenly, get gel to full dose 100g.
Claims (8)
1. medical composition is characterized in that, contains anti inflammation and heat resolution analgesic and Bulbus Allii elaboration products.
2. medical composition as claimed in claim 1 is characterized in that, the Bulbus Allii elaboration products are processing Bulbus Alliis.
3. medical composition as claimed in claim 1 or 2 is characterized in that, the anti inflammation and heat resolution analgesic is propanoic acid class medicine, salicylic acid medicine, phenyl amines medicine, pyrazoline ketone medicine or indoles medicine.
4. medical composition as claimed in claim 3 is characterized in that, propanoic acid class medicine is ibuprofen or loxoprofen.
5. medical composition as claimed in claim 3 is characterized in that, the salicylic acid medicine is aspirin or ethenzamide.
6. medical composition as claimed in claim 3 is characterized in that the phenyl amines medicine is an acetaminophen.
7. medical composition as claimed in claim 3 is characterized in that, pyrazoline ketone medicine is an isopropylantipyrine.
8. medical composition as claimed in claim 3 is characterized in that the indoles medicine is an indomethacin.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP347290/2002 | 2002-11-29 | ||
| JP2002347290 | 2002-11-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1717245A true CN1717245A (en) | 2006-01-04 |
Family
ID=32462881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2003801043061A Pending CN1717245A (en) | 2002-11-29 | 2003-11-27 | Medicinal composition |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JP4787499B2 (en) |
| CN (1) | CN1717245A (en) |
| AU (1) | AU2003284460A1 (en) |
| TW (1) | TW200413003A (en) |
| WO (1) | WO2004050110A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5796942B2 (en) * | 2009-09-28 | 2015-10-21 | 興和株式会社 | Loxoprofen-containing pharmaceutical composition |
| JP2011132225A (en) * | 2009-11-27 | 2011-07-07 | Kowa Co | Loxoprofen-containing medicinal composition |
| JP2011168580A (en) * | 2010-01-19 | 2011-09-01 | Daiichi Sankyo Healthcare Co Ltd | Pharmaceutical composition |
| JP6139050B2 (en) * | 2010-08-27 | 2017-05-31 | 興和株式会社 | Medicine |
| JP6334088B2 (en) * | 2011-12-27 | 2018-05-30 | 第一三共ヘルスケア株式会社 | Antipyretic analgesic composition |
| JP2012207038A (en) * | 2012-07-20 | 2012-10-25 | Ssp Co Ltd | Oral solid composition reduced in irritation to digestive tract |
| US9517217B2 (en) | 2012-08-03 | 2016-12-13 | Ehime University | Immune cell activation inhibitor and use thereof |
| JP2014055187A (en) * | 2013-12-25 | 2014-03-27 | Ss Pharmaceut Co Ltd | Oral solid composition reduced in irritation to digestive tract |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0196135A (en) * | 1987-10-07 | 1989-04-14 | Tanaka Kenichi | Remedy for hemorrhoid |
| JPH10182430A (en) * | 1996-12-26 | 1998-07-07 | Taisho Pharmaceut Co Ltd | Composition for external use |
| US6787164B2 (en) * | 2000-02-23 | 2004-09-07 | Bioselect Innovations, Inc. | Composition and method for treating the effects of diseases and maladies |
-
2003
- 2003-11-27 AU AU2003284460A patent/AU2003284460A1/en not_active Abandoned
- 2003-11-27 CN CNA2003801043061A patent/CN1717245A/en active Pending
- 2003-11-27 WO PCT/JP2003/015155 patent/WO2004050110A1/en active Application Filing
- 2003-11-27 JP JP2004556845A patent/JP4787499B2/en not_active Expired - Fee Related
- 2003-11-28 TW TW092133591A patent/TW200413003A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW200413003A (en) | 2004-08-01 |
| WO2004050110A1 (en) | 2004-06-17 |
| AU2003284460A1 (en) | 2004-06-23 |
| JPWO2004050110A1 (en) | 2006-03-30 |
| JP4787499B2 (en) | 2011-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6913795B2 (en) | Pharmaceutical composition containing loxoprofen 5 | |
| CN1296040C (en) | Medicinal compsns. | |
| CN101257894A (en) | Sustained release pharmaceutical compositions for highly water soluble drugs | |
| EP1992333B1 (en) | Flurbiprofen and muscle relaxant combinations | |
| JP2019019132A (en) | Stable pharmaceutical composition | |
| EP2074990B1 (en) | Controlled release flurbiprofen and muscle relaxant combinations | |
| JP5208729B2 (en) | Method for producing sustained-release tablets | |
| CN1717245A (en) | Medicinal composition | |
| JP5134802B2 (en) | Method for preventing reduction of bromhexine hydrochloride content | |
| WO2012091090A1 (en) | Antipyretic/analgesic composition | |
| JP4864369B2 (en) | Method for stabilizing thiamines | |
| JP2006124289A (en) | New solid preparation for dissolution in oral cavity | |
| US20150010627A1 (en) | New pharmaceutical compositions of flurbiprofen and glucosamin | |
| JP6073231B2 (en) | Stable pharmaceutical composition | |
| WO2013018766A1 (en) | Stable pharmaceutical composition | |
| RU2166937C1 (en) | Paracetamol-base drug | |
| JP2018090577A (en) | Ibuprofen-containing solid formulation excellent in disintegration properties | |
| JP2006124288A (en) | New solid preparation for dissolution in oral cavity | |
| CN101332177A (en) | Solid preparation containing ibuprofen, tranexamic acid and calcium silicate | |
| JP2014055187A (en) | Oral solid composition reduced in irritation to digestive tract | |
| CN101190206B (en) | Orally-administered solid composition capable of reducing irritation of digestion tube | |
| JP6113978B2 (en) | Antipyretic analgesic pharmaceutical composition | |
| WO2020208395A1 (en) | Oral herbal pain killer formulations | |
| WO2012153827A1 (en) | Stable drug composition | |
| KR20090032788A (en) | Pharmaceutical composition having improved rapid-acting property containing soybean polysaccharide as a rapid-acting disintegrant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20060104 |